![]() |
市場調查報告書
商品編碼
2149743
寵物焦慮緩解和鎮靜產品市場預測(2034 年)—按產品類型、寵物品種、分銷管道和地區分類的全球分析Pet Anxiety and Calming Products Market Forecasts to 2034 - Global Analysis By Product Type, Pet Type, Distribution Channel, and By Geography |
||||||
全球寵物焦慮緩解和鎮靜產品市場預計到 2026 年將達到 180 億美元,並在預測期內以 3.8% 的複合年成長率成長,到 2034 年達到 242 億美元。
寵物焦慮緩解和鎮靜產品旨在減輕伴侶動物的壓力、焦慮和行為問題,從而改善它們的健康和生活品質。該市場涵蓋多種產品類型,例如鎮靜補充劑、信息素產品、鎮靜穿戴設備、鎮靜玩具、外用鎮靜產品以及其他鎮靜產品。這些產品透過獸醫診所、寵物專賣店、超級市場和量販店、線上零售以及其他分銷管道銷售給犬、貓和其他寵物。人們對寵物心理健康的日益關注、寵物「擬人化」趨勢的增強以及寵物焦慮相關症狀的日益普遍,是推動市場擴張的主要因素。
人們越來越關注寵物心理健康和焦慮問題
人們對伴侶動物心理健康問題以及焦慮對寵物福祉影響的認知不斷提高,是推動寵物焦慮和鎮靜產品市場發展的主要動力。寵物飼主越來越關注寵物出現的壓力和焦慮徵兆。分離焦慮和噪音恐懼症症等行為問題困擾著許多寵物。隨著寵物越來越“擬人化”,人們對它們的情感健康也日益關注。這種對寵物心理健康日益增強的意識正在擴大對鎮靜產品的需求,從而支撐著市場的持續成長。
有效性證據有限,且有懷疑態度。
某些鎮靜劑產品缺乏科學證據,消費者對其療效持懷疑態度,這是限制市場發展的主要阻礙因素。並非所有產品都有可靠的臨床證據。一些消費者可能對天然鎮靜劑持懷疑態度。此外,其療效可能因動物而異。這些挑戰,例如缺乏科學證據和消費者的懷疑態度,可能會限制某些產品類型的市場成長。
天然來源且經臨床驗證的鎮靜成分創新
天然來源且經臨床驗證的鎮靜成分的持續創新為市場擴張帶來了巨大的機會。 L-茶胺酸、洋甘菊和CBD等成分正日益受到歡迎,支持其有效性的臨床研究也不斷增加。新的劑型提高了使用便利性。隨著產品品質和科學證據的不斷完善,創新鎮靜產品正在擴大其市場佔有率。
行為訓練和獸藥競爭
行為訓練和處方箋獸藥的競爭對寵物焦慮和鎮靜產品市場構成重大威脅。行為訓練有時無需使用這些產品即可解決行為問題。對於嚴重的焦慮,處方箋藥可能是更好選擇。這些替代方案可能會限制非處方鎮靜產品的市場成長。
新冠疫情擾亂了寵物們的日常生活,隨著飼主重返職場,寵物焦慮和鎮靜產品的市場需求加速成長。飼主重返辦公室後,寵物的分離焦慮情緒也隨之加劇。人們對寵物心理健康的關注度不斷提高,鎮靜產品的電商銷售額也隨之成長。即使在疫情結束後,人們對寵物福祉的關注依然持續,推動了市場成長。
在預測期內,「鎮靜劑補充劑」細分市場預計將佔據最大的市場佔有率。
在預測期內,「鎮靜補充劑」細分市場預計將佔據最大的市場佔有率,這主要得益於其易於獲取、劑型多樣以及消費者對天然鎮靜劑日益成長的偏好。鎮靜補充劑,包括咀嚼片、片劑和粉末,為緩解寵物焦慮提供了便利的選擇。此細分市場受益於產品供應量的增加和消費者意識的提高。作為最容易取得的鎮靜產品類型,補充劑在產品類型細分市場中佔據最大佔有率。
預計在預測期內,「狗」類產品將呈現最高的複合年成長率。
在預測期內,受犬隻數量龐大、犬隻焦慮症高發以及飼主對犬隻心理健康意識不斷提高等因素的推動,犬類市場預計將呈現最高的成長率。犬隻普遍有分離焦慮、噪音恐懼症和情境性壓力等問題。犬類市場受益於針對犬隻的廣泛產品開發。隨著犬隻飼養量和焦慮症意識的提高,預計犬隻將成為該細分市場中成長最快的寵物犬種。
在預測期內,北美預計將佔據最大的市場佔有率,這主要得益於較高的寵物擁有率、對寵物心理健康的高度重視以及成熟的產品供應。美國是該地區成長的主要驅動力,這主要歸功於消費者在寵物鎮靜劑上的巨額支出。人們對寵物焦慮問題的高度關注也推動了市場需求。成熟的零售和電商通路為市場准入提供了支援。憑藉高消費和高認知度,北美在市場中保持主導地位。
在預測期內,受寵物飼養量成長、寵物心理健康意識提升以及產品在歐洲各國供應範圍擴大等因素的推動,歐洲地區預計將呈現最高的複合年成長率。歐洲寵物飼主越來越關注寵物的福祉。產品創新和供應也不斷擴展。隨著這種意識的增強,歐洲在寵物焦慮緩解和鎮靜產品市場正經歷全球最快的成長。
According to Stratistics MRC, the Global Pet Anxiety and Calming Products Market is accounted for $18.0 billion in 2026 and is expected to reach $24.2 billion by 2034 growing at a CAGR of 3.8% during the forecast period. Pet anxiety and calming products are solutions designed to reduce stress, anxiety, and behavioral issues in companion animals, improving their well-being and quality of life. The market encompasses product types including calming supplements, pheromone-based products, calming wearables, calming toys, topical calming products, and other calming products. These products serve dogs, cats, and other pets through veterinary clinics and hospitals, pet specialty stores, supermarkets and mass retailers, online retail, and other distribution channels. Growing awareness of pet mental health, increasing pet humanization, and rising prevalence of anxiety-related conditions in pets are key drivers of market expansion.
Growing awareness of pet mental health and anxiety issues
The increasing recognition of mental health issues in companion animals and the impact of anxiety on pet well-being is a primary driver for the pet anxiety and calming products market. Pet owners are increasingly aware of signs of stress and anxiety in their animals. Behavioral issues including separation anxiety and noise phobias affect many pets. The humanization of pets has led to greater focus on emotional well-being. As awareness of pet mental health grows, demand for calming products expands, supporting sustained market growth.
Limited efficacy evidence and skepticism
Limited scientific evidence for some calming products and consumer skepticism about efficacy represent a major restraint for the market. Not all products have robust clinical evidence. Some consumers may be skeptical of natural calming remedies. Efficacy can vary between individual animals. These evidence and skepticism challenges may constrain market growth for certain product categories.
Innovation in natural and clinically validated calming ingredients
Continuous innovation in natural and clinically validated calming ingredients presents significant opportunities for market expansion. Ingredients including L-theanine, chamomile, and CBD are gaining popularity. Clinical studies supporting efficacy are increasing. Novel delivery formats improve convenience. As product quality and evidence improve, innovative calming products capture growing market share.
Competition from behavioral training and veterinary medications
Competition from behavioral training approaches and prescription veterinary medications poses significant threats to the pet anxiety and calming products market. Training may address behavioral issues without products. Prescription medications may be preferred for severe anxiety. These alternatives may limit market growth for over-the-counter calming products.
The COVID-19 pandemic accelerated pet anxiety and calming products market growth as pets experienced routine disruptions and owners returned to work. Separation anxiety increased as owners returned to offices. Awareness of pet mental health grew. E-commerce sales of calming products expanded. Post-pandemic, continued focus on pet well-being has supported market growth.
The Calming Supplements segment is expected to be the largest during the forecast period
The Calming Supplements segment is expected to account for the largest market share during the forecast period, driven by their accessibility, variety of formats, and growing consumer preference for natural calming solutions. Calming supplements including chews, tablets, and powders offer convenient options for managing pet anxiety. The segment benefits from expanding product availability and consumer awareness. As the most accessible calming product category, supplements maintain the largest product type segment share.
The Dogs segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Dogs segment is predicted to witness the highest growth rate, fueled by the large dog population, high prevalence of anxiety in dogs, and growing owner awareness of canine mental health. Dogs commonly experience separation anxiety, noise phobias, and situational stress. The segment benefits from extensive product development for dogs. As dog ownership and anxiety awareness grow, this pet type delivers the fastest segment growth.
During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership, strong awareness of pet mental health, and established product availability. The United States leads regional growth with substantial consumer spending on pet calming products. High awareness of pet anxiety issues drives demand. Well-established retail and e-commerce channels support market accessibility. With high spending and awareness, North America maintains its dominant market position.
Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR, driven by increasing pet ownership, growing awareness of pet mental health, and expanding product availability across European countries. European pet owners are increasingly focused on pet well-being. Product innovation and availability are expanding. As awareness grows, Europe delivers the fastest pet anxiety and calming products market growth globally.
Key players in the market
Some of the key players in Pet Anxiety and Calming Products Market include Nestle Purina PetCare, Mars, Incorporated, Zoetis Inc., Virbac S.A., Elanco Animal Health Incorporated, Ceva Sante Animale, PetIQ, LLC, Zesty Paws, PetHonesty, Vetoquinol S.A., NaturVet, THUNDERWORKS, Pet Remedy Ltd., Feliway, and PetSafe Brands.
In September 2026, Ceva Animal Health expanded its welfare initiative with Cats Protection across the United Kingdom, linking FELIWAY Optimum sales directly to sheltering and behavioral enrichment programs for surrendered cats showing severe anxiety.
In July 2026, Vetoquinol USA officially introduced Zylkene Plus across the United States, expanding its alpha-casozepine-based calming line with a dual-active formula designed for longer-term management of chronic environmental stress and behavioral anxiety in dogs and cats.
In February 2026, Nestle Purina PetCare convened global veterinary behaviorists and animal welfare scientists at the Purina Pro Plan Calming Care Symposium, presenting clinical research on modulating the canine gut-brain axis and highlighting regulatory milestones for the BL999 probiotic strain.
In January 2026, Elanco secured USDA approval for TruCan Ultra B (Oral), collaborating with the Fear Free movement to market low-volume, low-stress preventive administration formats aimed at reducing fear, anxiety, and clinic-induced distress in dogs.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW)
Regions are also represented in the same manner as above.